| Identifier |
20230314_nanos_posters_299 |
| Title |
VRDN-002, a Next-Generation Novel Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Results of a Phase 1 Trial |
| Creator |
Angela She; Rochelle Summerfelt; Brent Dickinson; Kelly Foster; Vahe Bedian; Barrett Katz |
| Affiliation |
(AS) (RS) (BD) (KF) (VB) (BK) Viridian Therapeutics Inc. |
| Subject |
Graves' Disease; Neuro-ophth & Systemic Disease (eg. MS, MG, Thyroid); Orbit/ocular Pathology |
| Description |
VRDN-002 is a half-life extended, novel antagonist antibody to the insulin-like growth factor-1 receptor (IGF-1R) under development for the treatment of thyroid eye disease (TED). Clinical and preclinical studies have confirmed IGF-1R antagonism can reduce the inflammation and proptosis that occur in TED. We present safety and pharmacokinetic/pharmacodynamic (PK/PD) results from our phase 1 clinical trial evaluating VRDN-002 dosed at 3-20 mg/kg. |
| Date |
2023-03-14 |
| Language |
eng |
| Format |
application/pdf |
| Type |
Text |
| Source |
2023 North American Neuro-Ophthalmology Society Annual Meeting |
| Relation is Part of |
NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| Collection |
Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu |
| Publisher |
Spencer S. Eccles Health Sciences Library, University of Utah |
| Holding Institution |
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416 |
| Rights Management |
Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
| ARK |
ark:/87278/s6ttxb8e |
| Setname |
ehsl_novel_nam |
| ID |
2335504 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6ttxb8e |
